Apellis Pharmaceuticals Inc (NASDAQ: APLS) stock jumped 0.81% on Monday to $49.50 against a previous-day closing price of $49.10. With 0.92 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.6 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $49.52 whereas the lowest price it dropped to was $47.90. The 52-week range on APLS shows that it touched its highest point at $94.75 and its lowest point at $19.83 during that stretch. It currently has a 1-year price target of $71.19. Beta for the stock currently stands at 0.93.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of APLS was up-trending over the past week, with a rise of 8.22%, but this was up by 6.68% over a month. Three-month performance surged to 60.92% while six-month performance fell -43.42%. The stock gained 14.48% in the past year, while it has lost -4.27% so far this year. A look at the trailing 12-month EPS for APLS yields -5.25 with Next year EPS estimates of -1.99. For the next quarter, that number is -0.88. This implies an EPS growth rate of 25.34% for this year and 56.64% for next year. EPS is expected to grow by 33.30% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -10.80%.
Float and Shares Shorts:
At present, 110.77 million APLS shares are outstanding with a float of 96.74 million shares on hand for trading. On Oct 30, 2023, short shares totaled 16.23 million, which was 13.70% higher than short shares on Sep 28, 2023. In addition to Dr. Cedric Francois M.D., Ph.D. as the firm’s Co-Founder, President, CEO & Director, Dr. Pascal Deschatelets Ph.D. serves as its Co-Founder & Chief Scientific Officer.
Through their ownership of 96.76% of APLS’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 49.22% of APLS, in contrast to 44.61% held by mutual funds. Shares owned by individuals account for 30.12%. As the largest shareholder in APLS with 12.80% of the stake, Wellington Management Co. LLP holds 15,167,044 shares worth 15,167,044. A second-largest stockholder of APLS, Avoro Capital Advisor LLC, holds 11,111,111 shares, controlling over 9.38% of the firm’s shares. EcoR1 Capital, LLC is the third largest shareholder in APLS, holding 10,899,859 shares or 9.20% stake. With a 4.97% stake in APLS, the Vanguard Health Care Fund is the largest stakeholder. A total of 5,894,862 shares are owned by the mutual fund manager. The Vanguard Total Stock Market ETF, which owns about 2.64% of APLS stock, is the second-largest Mutual Fund holder. It holds 3,131,124 shares valued at 152.36 million. Vanguard Small Cap Index Fund holds 2.18% of the stake in APLS, owning 2,581,205 shares worth 125.6 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for APLS since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With APLS analysts setting a high price target of $95.00 and a low target of $44.00, the average target price over the next 12 months is $71.19. Based on these targets, APLS could surge 91.92% to reach the target high and fall by -11.11% to reach the target low. Reaching the average price target will result in a growth of 43.82% from current levels.
Summary of Insider Activity:
Insiders traded APLS stock several times over the past three months with 7 Buys and 10 Sells. In these transactions, 483,219 shares were bought while 337,157 shares were sold. The number of buy transactions has increased to 86 while that of sell transactions has risen to 117 over the past year. The total number of shares bought during that period was 2,943,143 while 1,951,752 shares were sold.